Demographic and clinical characteristics of lithium‐treated older adults with bipolar disorder.

Saved in:
Bibliographic Details
Title: Demographic and clinical characteristics of lithium‐treated older adults with bipolar disorder.
Authors: Forlenza, Orestes V. (AUTHOR), Hajek, Tomas (AUTHOR), Almeida, Osvaldo P. (AUTHOR), Beunders, Alexandra J. M. (AUTHOR), Blumberg, Hilary P. (AUTHOR), Briggs, Farren B. S. (AUTHOR), De‐Paula, Vanessa J. R. (AUTHOR), Dols, Annemiek (AUTHOR), Eyler, Lisa T. (AUTHOR), Forester, Brent P. (AUTHOR), Gildengers, Ariel (AUTHOR), Jimenez, Esther (AUTHOR), Korten, Nicole C. M. (AUTHOR), Lafer, Beny (AUTHOR), McWhinney, Sean R. (AUTHOR), Mulsant, Benoit (AUTHOR), Rej, Soham (AUTHOR), Sarna, Kaylee (AUTHOR), Schouws, Sigfried (AUTHOR), Sutherland, Ashley (AUTHOR)
Source: Acta Psychiatrica Scandinavica. Nov2022, Vol. 146 Issue 5, p442-455. 14p. 3 Charts.
Subjects: Older people, Demographic characteristics, Bipolar disorder, Lithium carbonate, Psychiatric diagnosis, Neuroleptic malignant syndrome
Abstract: Objectives: There is limited information on the characteristics of older adults with bipolar disorder (OABD) treated with lithium, along with safety concerns about its use by older adults. The aim of the present study is to describe the demographic and clinical characteristics of OABD receiving lithium therapy, using data from the Global Ageing & Geriatric Experiments in Bipolar Disorder (GAGE‐BD). Experimental Procedures: Cross‐sectional analysis of the GAGE‐BD dataset to determine differences and similarities between lithium users and non‐users. We analysed data from 986 participants aged 50 years or older (mean age 63.5 years; 57.5% females) from 12 study sites. Two subgroups ('Lithium'; 'Non‐lithium') were defined according to the current prescription of lithium. We compared several outcomes between these groups, controlling for age, gender, and study site. Results: OABD treated with lithium had lower scores on depression rating scales and were less likely to be categorised as with moderate or severe depression. There was a lower proportion of lithium users than non‐users among those with evidence of rapid cycling and non‐bipolar psychiatric diagnoses. Assessment of global cognitive state and functionality indicated better performance among lithium users. The current use of antipsychotics was less frequent among lithium users, who also reported fewer cardiovascular comorbidities than non‐users. Conclusion: We found several potentially relevant differences in the clinical profile of OABD treated with lithium compared with those treated with other mood stabilisers. However, the interpretation of the present results must take into account the methodological limitations inherent to the cross‐sectional approach and data harmonisation. [ABSTRACT FROM AUTHOR]
Copyright of Acta Psychiatrica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
Description
Abstract:Objectives: There is limited information on the characteristics of older adults with bipolar disorder (OABD) treated with lithium, along with safety concerns about its use by older adults. The aim of the present study is to describe the demographic and clinical characteristics of OABD receiving lithium therapy, using data from the Global Ageing & Geriatric Experiments in Bipolar Disorder (GAGE‐BD). Experimental Procedures: Cross‐sectional analysis of the GAGE‐BD dataset to determine differences and similarities between lithium users and non‐users. We analysed data from 986 participants aged 50 years or older (mean age 63.5 years; 57.5% females) from 12 study sites. Two subgroups ('Lithium'; 'Non‐lithium') were defined according to the current prescription of lithium. We compared several outcomes between these groups, controlling for age, gender, and study site. Results: OABD treated with lithium had lower scores on depression rating scales and were less likely to be categorised as with moderate or severe depression. There was a lower proportion of lithium users than non‐users among those with evidence of rapid cycling and non‐bipolar psychiatric diagnoses. Assessment of global cognitive state and functionality indicated better performance among lithium users. The current use of antipsychotics was less frequent among lithium users, who also reported fewer cardiovascular comorbidities than non‐users. Conclusion: We found several potentially relevant differences in the clinical profile of OABD treated with lithium compared with those treated with other mood stabilisers. However, the interpretation of the present results must take into account the methodological limitations inherent to the cross‐sectional approach and data harmonisation. [ABSTRACT FROM AUTHOR]
ISSN:0001690X
DOI:10.1111/acps.13474